Chico, CA (May 17, 2006) – Radiation oncology software company Prowess, Inc. is very pleased to announce the release of its Panther 4.3 Treatment Planning System. Among the many new features of this Windows based TPS is the ability to deliver Intensity Modulated Radiation Treatments (IMRT) with a solid brass compensator.

Chico, CA (August 18, 2005) – Radiation oncology software company Prowess, Inc. is very pleased to announce the release of their Jaws-Only DAO IMRT – Panther 4.2. This remarkably innovative product allows users to create and deliver Intensity Modulated Radiation Therapy (IMRT) plans without using a multi-leaf collimator. Jaws-Only DAO IMRT, recently launched at the 47th Annual Meeting of the American Association of Physicists in Medicine in Seattle, and recently showcased on Health Journal Television hosted by General Alexander Haig, will no doubt make a significant contribution to the oncology field.

Radiation oncology software company Prowess, Inc. has released Panther 4.1, which will help to improve the quality of life for cancer patients around the world. Panther, already known for its user friendly interface, single platform, fast calculation engine, and patented DAO IMRT technology, has now become even more powerful. True to form, the latest version includes a variety of enhancements and new features sure to set new standards within the treatment planning software arena.

Developed in cooperation with researchers at University of Maryland (College Park, MD), Prowess Panther™ DAO IMRT uses patented technology to develop treatment plans that are more accurate, take less time and deliver less radiation than standard IMRT solutions. The efficiencies of Prowess Panther DAO IMRT allow substantially more cancer patients access to the benefits of IMRT. By contrast, standard IMRT has been prescribed to only about 20% of cancer patients, mainly due to the lengthy – and more costly – treatment sessions.

Inverse Brachy offers accuracy in dose delivery while lowering radiation to normal tissue. In comparison to other brachytherapy planning systems, based on 30 prostate cases with prescribed dose delivered to 98% of the gland, Prowess’ Inverse Brachy improved conformity ranges from 10-20%; reduced urethra dose by 21%; reduced rectum dose by 15%; used fewer seeds (~15%) and needles (10%); and resulted in an under-dose of within 3% of the prescribed dose.